UKESAD: PROFESSOR ROGER D WEISS

...is professor of Psychiatry at Harvard Medical School and clinical director of its affiliate McLean Hospital alcohol and drug abuse treatment programme. http://www.mclean.harvard.edu/research/clinicalunit/adatp.php

He has focused his research and clinical interests on the evaluation and treatment of 1) patients with cocaine dependence, and 2) substance dependent patients with psychiatric illness. In the 1980s, he was among the first researchers to report the high rate of psychiatric disorders in drug dependent patients. At that time, psychiatrists had little interest in addiction; his work helped to emphasise the importance of psychiatric expertise in treating this population. He next conducted studies relevant to the daily practice of addiction treatment: part of his strength as a researcher has come from his extensive clinical experience as director of the addiction treatment program at McLean Hospital since 1980.

This experience taught the types of questions that clinicians face regularly; his research has thus focused on these issues. For example, he has focused on the process of making psychiatric diagnoses in substance dependent patients (e.g., the utility of various standardised diagnostic instruments, depression rating scales, and biological markers) as well as the importance of recognising heterogeneity within the substance dependent population (e.g., gender differences in cocaine abusers, differences related to the primary drug of choice).

In recent years, his work has evolved from an emphasis on evaluation to a focus on treatment strategies for discrete subgroups of substance dependent and dually diagnosed patients. Most recently, he developed the first treatment designed specifically for patients with coexisting bipolar disorder and substance dependence; pilot-testing has been promising. He is currently testing this treatment both in a randomised controlled trial and in a study designed to test its effectiveness in community-based settings.

He has worked with Dr Lisa Najavits to develop and test a treatment for drug dependent women with post-traumatic stress disorder. As PI of the Harvard site of the NIDA Collaborative Cocaine Treatment Study, the largest controlled study of psychosocial treatment of cocaine dependence ever conducted, he was the first researcher to examine the role of self-help attendance among cocaine dependent patients.

He is currently PI of the Harvard site of the NIAAA-funded Project COMBINE, a multicentre site examining optimal combinations of pharmacotherapy and psychotherapy for alcohol dependent patients. He is also PI for the Harvard site on a NIDA-funded study of Genetics of Cocaine Dependence. Most recently, he became PI for the Harvard University Northern New England Node of the NIDA Clinical Trials Network, a multisite study designed to develop and implement drug abuse treatment studies in community treatment programs.

Finally, he is co-iInvestigator or consultant on other federally funded projects, including the NIMH-funded Systematic Treatment Enhancement Program for Bipolar Disorder, a multisite trial trial examining optimal treatment strategies for patients with bipolar disorder; he is Substance Abuse Pathway Leader for this study.

Funding.

Weiss is currently PI on five federally funded grants. There is a grant funded by the NIDA Behavioral Therapies Development Program to test a treatment he developed for patients with bipolar disorder and substance dependence: Integrated Group Therapy. He is nearing the end of a study comparing that in a controlled trial with Group Drug Counselling. In Integrated Group Therapy, patients focus on both disorders at once, while in Group Drug Counselling, a “parallel” model of treatment takes place, in which the group therapy focuses on their substance abuse and they are told to focus on their bipolar disorder treatment with their psychiatrist. In the study nearing its completion, all therapists conducting Integrated Group Therapy are highly trained professionals with advanced degrees and cognitive-behavioural training. He recently received a grant from NIDA to see if a modified version of this treatment could be delivered by front-line drug counsellors; this is part of an interest on the part of NIDA to increase the likelihood that innovative treatments for drug dependence will be adopted by community drug treatment programmes.

He is PI of the NIAAA-funded Project, “COMBINE,” which compares combinations of pharmacologic and behavioural treatments of alcohol dependence. The study medications are acamprosate, naltrexone and the combination of the two; the behavioural treatments are a brief, HMO-based medical management and a state-of-the-art psychotherapeutic treatment of alcohol dependence.

The fourth project, on which he is Harvard site PI, is Genetics of Cocaine Dependence, funded by NIDA. This project is examining genotypic and phenotypic patterns among families in which two or more siblings are diagnosed with cocaine dependence.

Finally, he is PI of the Harvard University Northern New England Node of the NIDA Clinical Trials Network (CTN). The CTN is a nationwide effort by NIDA to improve the overall quality of drug abuse treatment by forging a partnership between academic research centers and community drug abuse treatment programs. Researchers and community treatment program clinicians work with each other to develop and carry out research studies in community programs.

In addition to these projects, Weiss has an Independent Scientist Award from the National Institute on Drug Abuse on “Treatment of Drug Dependence and Psychiatric Illness. He is co-Investigator on a NIDA-funded study with Dr. Shelly Greenfield, developing a group therapy specifically designed for women, based on recent scientific findings about gender differences in the course of substance use disorder. He was also co-investigator on two studies with Dr. Lisa Najavits, examining group therapy for women with posttraumatic stress disorder and drug dependence, as well as adolescent girls with the same disorders. Although funding for these studies has ended, they are currently analysing data and writing up findings. He is the Substance Abuse Pathway Leader and Co-Investigator for the NIMH-funded multisite trial, “Systematic Treatment Enhancement Program for Bipolar Disorder.” In this project, he examines brief interventions for substance use disorders among patients with bipolar disorder, as they naturalistically occur in clinical practice.

Degree(s):

1972 AB Harvard College

1976 MD Tufts University School of Medicine

Residency:

1979 McLean Hospital

Board Certifications(s):

ABPN, Psychiatry, with added qualifications in Addiction Psychiatry

EDUCATION:

1972 A.B. cum laude, Harvard College

1976 M.D. Tufts University School of Medicine

POSTDOCTORAL TRAINING:

1976-1979 Resident in Psychiatry, McLean Hospital, Belmont, MA

1978-1979 Resident, Department of Medicine (Consultation-Liaison Psychiatry), Peter Bent Brigham Hospital

1978-1979 Fellow in Psychiatry, Massachusetts Institute of Technology

1978-1979 Chief Resident, Outpatient Clinic, McLean Hospital

LICENSURE AND CERTIFICATION:

1978 Massachusetts License Registration, #42785

1980 American Board of Psychiatry and Neurology, Certificate

1993 Added Qualifications in Addiction Psychiatry, Certificate

ACADEMIC APPOINTMENTS:

1976-1979 Clinical Fellow in Psychiatry, Harvard Medical School

1979-1980 Clinical Instructor in Psychiatry, Harvard Medical School

1980-1985 Instructor in Psychiatry, Harvard Medical School

1986-1990 Assistant Professor of Psychiatry, Harvard Medical School

1990-2003 Associate Professor of Psychiatry, Harvard Medical School

2003 Professor of Psychiatry, Harvard Medical School

HOSPITAL APPOINTMENTS:

1979-1986 Assistant Psychiatrist, McLean Hospital

1987-1992 Associate Psychiatrist, McLean Hospital

1992- Psychiatrist, McLean Hospital

OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS:

1984-1995 Substance Abuse Consultant, Boston Red Sox Baseball Club

1984-1991 Substance Abuse Consultant, Health Data Institute, Lexington, MA

1986 Consultant, Massachusetts Department of Public Health: Division of Alcoholism and

Drug Rehabilitation

1988 Visiting Professor Program, University of Pittsburgh School of Medicine

1988-1990 Substance Abuse Consultant, The Better Homes Foundation, Needham, MA

1988-1990 Substance Abuse Consultant, Center for Consumer Healthcare Information, Irvine, CA

1991-1997 Board of Advisors, Institute for Health Psychology, Dedham, MA

1993-1994 Consultant, World Health Organization Cocaine Project

1995-1997 Consultant, Florida Department of Corrections

1995 Visiting Professor, King Saud University, Riyadh, Saudi Arabia

1999- National Advisory Board, National Alcohol Screening Day

HOSPITAL AND HEALTH CARE ORGANISATION SERVICE RESPONSIBILITIES:

1979-1980 Psychiatrist in Charge (half-time), Codman I (a general psychiatric unit), McLean Hospital

1980-1985 Psychiatrist in Charge, Drug Dependence Treatment Unit, McLean Hospital

1986-1988 Director, Alcohol and Drug Abuse Treatment Center, McLean Hospital

1988-Present Clinical Director, Alcohol and Drug Abuse Program, McLean Hospital

MAJOR ADMINISTRATIVE RESPONSIBILITIES:

1988-Present Clinical Director, Alcohol and Drug Abuse Program, McLean Hospital

Responsible for overall administration of the McLean Hospital Alcohol and Drug Abuse Treatment Program, including a 12-bed locked inpatient unit, 3 residential treatment programmes (including 1 satellite program) with a total of 40 beds, a partial hospital program, an outpatient program, a consultation program, and a clinical esearch programme.

MAJOR COMMITTEE ASSIGNMENTS:

McLean Hospital:

1976-1979 Resident Evaluation Committee

1984 Committee on Impaired Employees

1984-1985, 1988-1990 Clinical Case Conference Committee

1986-1989 Infections Committee

1988-1992 Clinical Operations Committee

1989-1993 Quality Assurance Committee

1989- Resident Education Training Committee

1989-1993 Utilization Review Committee

1989- Resident Selection Committee

1990- Research Committee

1992- Patient Care Coordinating Committee

1993- General Executive Committee

1996 Joint Conference Committee

2001- Continuing Education Committee

Harvard University/Harvard Medical School:

1986-1988 HMS Committee on AIDS

1998-2001 Harvard University Mind/Brain/Behavior Substance Abuse Working Group

1999- Faculty Fellow, Harvard University Mind/Brain/Behavior Program

1998-1999 HMS Review Committee, Division on Addictions

Partners HealthCare System, Inc.:

1996-2001 Co-Chair, Substance Abuse Work Group

1999- Mental Health Research Committee

1999- Mental Health Education Committee

Regional:

1982- Committee on Alcoholism and the Addictions, Massachusetts Psychiatric Society,

Member

1982-1985 Impaired Physicians' Committee, Massachusetts Psychiatric Society, Member

National:

1986-1989 Research Committee, American Academy of Psychiatrists in Alcoholism and

Addictions, Member

1988- Special Review Committees, National Institute on Drug Abuse, Member

1988-1994 Advisory Board, DSM-IV Work Group on Alcohol and Substance Abuse, Member

1989-1990 Scientific Programs and Research Committee, American Academy of Psychiatrists in Alcoholism and Addictions, Co-Chair

1991-1995 Scientific Program Committee, American Academy of Addiction Psychiatry, Chair

1992-1995 American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders, Member

1996-2001 National Institute on Drug Abuse Initial Review Group Member: Treatment Research Subcommittee

1999-2001 Research Section, American Academy of Addiction Psychiatry, Chair

1999- Committee for Added Qualifications in Addictions, American Board of Psychiatry and Neurology, Member

2001- American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders, Vice Chair

2003- Treatment Research Subcommittee, National Institute on Drug Abuse Initial Review Group (NIDAIRG), Member

PROFESSIONAL SOCIETIES:

1979-2002 American Psychiatric Association (Fellow, 1988)

1979- Massachusetts Psychiatric Society, Member

1985-1993 American Society of Addiction Medicine, Member

1985- American Academy of Addiction Psychiatry (formerly American Academy of

Psychiatrists in Alcoholism and Addictions), Member

1986-1993 American Psychopathological Association, Member

1987-1989 AIDS Task Force, Harvard Medical School, Department of Psychiatry, Member

1998- College on Problems of Drug Dependence, Member

2003- American Psychiatric Association, Distinguished Fellow

COMMUNITY SERVICE RELATED TO PROFESSIONAL WORK:

1996- Board of Directors, Greater Boston Council on Alcoholism

1999- Vice President, Greater Boston Council on Alcoholism

EDITORIAL BOARDS:

Editorial Board Member

1992- American Journal of Drug and Alcohol Abuse

1998- Journal of Clinical Psychiatry

1999- Harvard Review of Psychiatry, Field Editor

1999- Editorial Advisory Committee, Trastornos Adictivos (Addictive Disorders)

1999- American Journal on Addictions (Associate Editor for Book Reviews)

2001- Current Psychiatry Reports, Substance Use Disorders Editor

2001- Current Psychiatry

Reviewer

1985- Journal of Nervous and Mental Disease

1986- Annals of Allergy

1987- Social Science and Medicine

1988- Journal of Studies on Alcohol

1988- New York State Journal of Medicine

1989- Archives of General Psychiatry

1989- Journal of the American Medical Association

1989- Journal of Psychiatric Research

1990- Drug and Alcohol Dependence

1990- American Journal on Addictions

1991- Addiction

1991- American Journal of Psychiatry

1994- Harvard Review of Psychiatry

1994- Journal of Clinical Psychiatry

1996- New England Journal of Medicine

AWARDS AND HONORS:

1969 Detur Book Award

1969 John Harvard Scholarship

1978 Nominee, Laughlin Fellowship, American College of Psychiatrists

1979 National Psychiatric Endowment Fund Award

1988 Fellow, American Psychiatric Association

1996 Partners In Excellence Award, Partners HealthCare System, Inc.

1999 Author, Distinguished Scholar Series, American Journal on Addictions

1999, 2000 Faculty Member, American Psychiatric Association Research Colloquium for Junior Investigators

2003 Distinguished Fellow, American Psychiatric Association

2007 14th Annual H. David Archibald Award for Outstanding Research and/or Practice in the Addictions, Centre for Addiction and Mental Health, Toronto

RESEARCH, TEACHING, AND CLINICAL CONTRIBUTIONS:

Research Funding Information:

Past

1986-1991 NIDA P50 DA04059 Co-Investigator Polydrug Abuse in Women: NIDA Clinical

Research Center

1989-1995 NIDA R18 DA-6116 Co-Investigator Treatment Efficacy for Drug Abuse and AIDS Prevention

1989-1994 NIDA R29 DA05944 PI Predictors of Outcome in Cocaine Dependence

1995-1998 NIAAA R29 AA09881 Co-Investigator Gender Differences in Recovery from Alcohol Dependence

1995-1998 NIDA Y01 DA50038 Consultant NIDA/VA Substance Abuse Medication Development Center

1991-1999 NIDA U10 DA07693 PI Psychosocial Treatment of Cocaine

Use Disorder

1996-1999 NIMH R01 MH54317 Consultant Substance Abuse Comorbidity in First-Episode

Mania

1993-2000 NIDA R01 DA08631 Co-PI Group Cognitive Behavior Therapy for Dual

Diagnosis Women

1998-2001 NIAAA R21 AA12181 Co-Investigator Cognitive-Behavior Therapy for PTSD/AUD

Adolescent Girls

1998-2001 NIMH R01 MH58288 Co-Investigator Mental Illness, Comorbidity and Mortality Diagnosis Women

1997-2007 NIDA K02 DA00326 PI Independent Scientist Award: Treatment of Drug Dependence and Psychiatric Illness

Present

1991- NIDA T32 DA07252 Program Faculty Drug Abuse Research Training Program

1992- Dr. Ralph and Marian C. PI Research on Substance Abuse Falk Medical Research Trust

1994- NIDA R01 DA09400 PI A Relapse Prevention Group for Bipolar Substance Abusers

1995- NIDA R01 DA09657 Co-Investigator Cocaine Effects: Ethnic, Gender and Hormonal Factors

1999- NIMH R01 MH58170 Consultant Substance Abuse in First-Episode Mania

1997- NIAAA U10 AA11756 PI Combined Behavioral and Pharmacologic Treatment of Alcoholism

1998- NIMH N01 MH80001 Co-Investigator; Systematic Treatment Enhancement Program Substance Abuse for Bipolar Disorder

Pathway Leader

1999- NIDA R01 DA12849 Harvard Site PI Genetics of Cocaine Dependence

2002- NIDA R01 DA15434 Co-Investigator Recovery Group for Women with Substance Use Disorders

2002- NIDA R01 DA15968 PI Modifying Group Therapy for Bipolar Substance Abusers

2002- NIDA U10 DA15831 PI NIDA Clinical Trials Network: Harvard University Northern New England Node

2003- NIAAA R21 AA13423 Consultant Reliability Generalization of Alcohol

Screening Measures

2007- NIDA K24 DA022288 PI Midcareer Investigator Award in Patient-Oriented Research: Mentoring in Drug Abuse and Dual Diagnosis Research

Local Contributions:

Medical School Courses

1986-1988 Expert Faculty Resource, Life Cycle course, New Pathways Program, Harvard Medical School

1986- Faculty, Harvard Medical School course 700 MJ: Psychopathology and Introduction to Clinical

Psychiatry; Lecturer on substance use disorders: 12-20 students, two hours

1989-1991, Faculty, Harvard Medical School course on Clinical Pharmacology and Therapeutics; Lecturer

2002- on pharmacotherapy of substance use disorders: 25 students, one hour

1993- Faculty, Harvard Medical School course on Substance Abuse: Addictive Process, Teach seminar on

treatment of substance use disorders once per course: approximately 10 students, one hour

1995 Nominee, Harvard Medical School Award for Excellence in Mentoring

Graduate Medical Courses

1978-1979 Seminar Leader, McLean Hospital Outpatient Clinic, McLean Hospital

1982- Seminar Leader, Taught seminars on substance use disorders for first and second year psychiatric residents, McLean Hospital; 10 residents, six hour-long seminars per year

1985- Seminar Leader, Taught seminars on substance use disorders for psychiatric residents at Beth Israel Hospital, Brockton Veterans Administration Hospital, Massachusetts Mental Health Center, Longwood Residency Program; approximately 10 residents, up to two seminars a year (none in some years) Invited Teaching Presentations (since 1991)

1/31-2/2/91 New England Educational Institute, “Clinical Approaches to Alcohol and Drug Abuse”

3/13/91 Lawyers Concerned for Lawyers, Boston, “Substance Abuse”

3/18/91 Mount Auburn Hospital Department of Medical Education, “Cocaine”

4/30/91 Mount Auburn Hospital Grand Rounds, “Adolescent Alcohol and Drug Abuse”

8/26-30/91 New England Educational Institute, “Clinical Approaches to Alcohol and Drug Abuse”

10/9/91 Massachusetts Psychiatric Society, “Alcohol and Drug Abuse”

10/24/91 Charles River Hospital Grand Rounds, “Substance Abuse and Psychiatric Illness: Clinical Approaches to the Dual Diagnosis Patient”

11/22/91 Salem Hospital Grand Rounds, “Cocaine”

2/11/92 Pembroke Hospital Academic Conference Series, “Diagnosis and Treatment of the Dually Diagnosed Patient”

3/6/92 Harvard Medical School/Cambridge Hospital, Understanding and Treating the Addictions Conference, “A Clinical Approach to the Dually Diagnosed Patient”

5/14/92 McLean Hospital Continuing Education, “Dual Diagnosis: Evaluation and Treatment”

5/22/92 Brockton Veterans Administration Hospital, “A Clinical Approach to the Dually Diagnosed Patient”

6/10/92 New England Deaconess Hospital, “Alcohol and Drug Abuse”

7/30/92 Newton-Wellesley Hospital, “Dual Diagnosis in the Treatment of Substance Abuse”

8/24-28/92 New England Educational Institute, “Clinical Approaches to Alcohol and Drug Abuse”

9/17/92 Cape Cod Symposium on Addictive Disorders, “A Clinical Approach to the Dual Diagnosis Patient”

9/18/92 Harvard Medical School Division on Addictions, “Cocaine Abuse and Dependence”

9/29/92 Brigham and Women’s Hospital Grand Rounds, “Dual Diagnosis”

3/10/93 Melrose-Wakefield Hospital, “Diagnosis and Treatment of Cocaine Abuse”

8/23-27/93 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

9/30/93 North River Foundation, Inc., Cape Cod Symposium on Addictive Disorders, “New Clinical

and Research Findings in Cocaine Dependence”

11/17/93 Marlborough Hospital, “Dual Diagnosis: Substance Dependence and Psychiatric Disorders”

11/18/93 Massachusetts Institute of Technology Medical Department, “Alcohol and Drug Abuse”

2/7/94 Massachusetts Mental Health Center Resident Training, “Clinical Aspects of Cocaine/Stimulants”

3/4/94 Harvard Medical School/Cambridge Hospital, Treating the Addictions: Clinical Controversies

Conference, “Why Integrate Psychopharmacological and Psychological Treatment Approaches with

Substance Abusers”

5/5/94 Newton-Wellesley Hospital, “New Findings on Cocaine Abuse”

5/6/94 Massachusetts Mental Health Center Psychopharmacology Lecture Series, “Cocaine Clinical

and Research Update”

7/11-15/94 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

3/1/95 Harvard Longwood Psychiatry/Resident Training – Medical Psychiatry Seminar, “Cocaine/Stimulants”

3/8/95 Medical Center of Central Massachusetts, Worcester, “Dually Diagnosed Patients”

3/10/95 North Shore Medical Center, “Major Mental Illness and Substance Abuse”

3/20/95 Boston College School of Nursing – Advanced Pharmacology course, “Psychopharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

3/31/95 McLean Hospital Academic Conference, “Cocaine Abuse: A Clinical Update”

6/2/95 Brockton Veterans Medical Center, “Substance Abuse: How Do We Effectively and Creatively Use Our Resources?”

8/1/95 Big Brother Association of Greater Boston, “Substance Abuse”

8/21-25/95 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

11/27/95 Cambridge Hospital Grand Rounds, “Cocaine Abuse – A Clinical Update”

2/5/96 Boston College School of Nursing – Advanced Pharmacology course, “Psychopharmacologic Treatment of Substance Abuse Disorders and Dual Diagnosis”

3/28/96 Mental Health Associates of Greater Springfield, Springfield, MA, “Psychopharmacology of Dually Diagnosed Patients”

4/19/96 McLean Hospital, Substance Abuse and Violence Conference, “Cocaine and Alcohol Abuse”

7/25/96 Berkshire Area Health Education Center, 12th Annual Berkshire Medical Conference, Hancock, MA –Special Challenges in General Medicine, “Therapeutic Approaches To Drug Abuse”

8/19-23/96 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

10/10/96 Harvard Community Health Plan, Geriatric Mental Health Training Series, “Evaluation and Treatment of Alcohol or Drug Problems in Older Individuals”

10/25/96 Harvard Medical School, Addiction Medicine: A Course for Clinicians, “Cocaine Abuse and Dependence”

11/20/96 Cambridge Hospital Advanced Psychopharmacology Seminar, “Dual Diagnosis Patients”

12/12/96 Harvard University Health Services Grand Rounds, “Update on Cocaine Abuse”

2/10/97 Boston College Advanced Psychopharmacology course, “Psychopharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

2/20/97 University of Massachusetts Medical School, Psychiatry Grand Rounds, “Psychotherapy of Patients with Substance Use Disorders”

4/18/97 McLean Hospital, Bipolar Disorder: Comorbid Disorder, Diagnosis and Pharmacological Management Conference, “Bipolar Disorder with Substance Abuse”

4/24/97 Baystate Medical Center Grand Rounds, “Treating Dual Diagnosis Patients on an Adult Psychiatry Inpatient Unit”

5/29/97 McLean Hospital Academic Conference, “Update on Pharmacotherapy of Substance Use Disorders and Dual Disorders”

8/10-17/97 Brigham & Women’s Hospital Intensive Review of Internal Medicine, “Substance Abuse”

8/18-22/97 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

9/12/97 Harvard Medical School/Cambridge Hospital Suicide Symposium, “Substance Abuse and Suicide”

9/26/97 Department of Mental Health, Commonwealth of Massachusetts, Dual Diagnosis Conference, “Dual Diagnosis: Elements of Pharmacotherapy”

10/25/97 Harvard Medical School Addiction Medicine conference, “Cocaine”

11/15/97 Massachusetts Psychiatric Society, Psychopharmacology Update Conference, “Psychopharmacological

Management of Bipolar Patients Who Are Abusing Alcohol and Drugs”

2/9/98 Boston College Prescribing Practices for Psychopharmacology course, “Psychopharmacologic Treatment of Substance Abuse”

2/12/98 University of Massachusetts Medical Center, Worcester, “Substance Abuse and Mood Disorders”

4/10/98 McLean Hospital Academic Conference, “Pharmacotherapy of Substance Use Disorders and Dually Diagnosed Patients”

5/5/98 Harvard Medical School Consolidated Department of Psychiatry DMH Teleconference Series, “Dual Diagnosis – Management and Comorbidity Issues”

5/13/98 Brigham & Women’s Hospital Addiction Lecture Series, “Therapeutic Approaches to Alcohol and Substance Abuse”

5/27/98 Center for Mental Health, Waltham, “Pharmacotherapy of Substance Use Disorders and Dually Diagnosed Patients”

7/27-31/98 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

8/12/98 Brigham & Women’s Hospital, Intensive Review of Internal Medicine, “Drug and Alcohol Abuse”

10/21/98 Quincy Mental Health Center, “Substance Abuse”

11/12/98 Tufts University School of Medicine, 2nd Year Students, Addiction Medicine Lecture, “Cocaine and Stimulants”

11/16/98 Westwood Lodge Hospital Psychopharmacology Seminar, Westwood, MA, “Substance Abuse and Bipolar Disorder”

12/10/98 McLean Hospital, Psychopharmacology Grand Rounds, “Pharmacotherapy of Patients with Substance Use Disorders and Dually Diagnosed Patients”

2/8/99 Boston College Prescribing Practices for Psychopharmacology course, “Pharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

3/9/99 Lahey Clinic Psychiatric Grand Rounds, Burlington, MA, “Substance Abuse and Mood Disorders”

3/11/99 Deaconess-Waltham Hospital, “Pharmacotherapy of Patients with Substance Use Disorders and Dually Diagnosed Patients”

4/5/99 Veterans Administration Outpatient Clinic, Boston, “Substance Abuse and Depression: A Clinical Overview”

6/23/99 Harvard University Kennedy School of Government seminar Merging Perspectives on Drugs and Crime: A Cross-Agency Approach, “Treatment of Substance Use Disorders”

7/6/99 Boston University School of Public Health, Center for Substance Abuse Prevention Faculty Development Program, “Substance Abuse Treatment Modalities and Their Effectiveness”

8/16-20/99 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

10/7/99 Brockton VA Medical Center Grand Rounds, “Substance Abuse in Bipolar Illness”

11/8/99 Tufts University School of Medicine, 2nd Year medical students, “Cocaine and Other Psychostimulants”

12/13/99 Massachusetts Commission for the Blind, “Alcohol and Substance Abuse”

2/3/00 Newton-Wellesley Hospital, “Psychotherapy of Substance Use Disorders”

2/7/00 Boston College Prescribing Practices for Psychopharmacology course, “Pharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

6/30/00 Massachusetts General Hospital, “Bipolar Disorder and Substance Abuse”

7/20/00 Harvard University Kennedy School of Government seminar Merging Perspectives on Drugs and Crime: A Cross-Agency Approach, “Treatment of Substance Use Disorders”

8/21-25/00 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

4/30/01 Boston College Prescribing Practices for Psychopharmacology course, “Pharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

8/6-10/01 New England Educational Institute, “Therapeutic Approaches to Alcohol and Drug Abuse”

10/31/01 Tufts University School of Medicine, 2nd Year medical students, “Cocaine and Other Psychostimulants”

11/1/01 Harvard University Health Services: “Substance Abuse and Mood Disorders”

4/1/02 Boston College Prescribing Practices for Psychopharmacology course, “Pharmacologic Treatment of Substance Use Disorders and Dual Diagnosis”

8/5-9/02 New England Educational Institute, “Substance Abuse and Dual Diagnosis: New Treatment Approaches”

10/18/02 Harvard Medical School Division on Addictions Course on Addiction Medicine: New Strategies for a New Millennium: “New Behavioral Therapies for Drug Dependence”

11/18/02 Tufts University School of Medicine, 2nd Year medical students, “Cocaine and Other Psychostimulants”

1/16/03 McLean Hospital Academic Conference, “Substance Abuse and Mood Disorders”

2/20/03 Brockton VA Hospital Grand Rounds: “Substance Abuse and Mood Disorders”

4/8/03 Westwood Lodge Hospital Academic Conference, “Substance Abuse and Mood Disorders”

4/10/03 Silver Hill Hospital, New Canaan, CT, “Update in Addiction Psychiatry and Pain Management”

4/24/03 St. Francis Health System, Tulsa, OK, “Substance Abuse and Dual Diagnosis: New Treatment Approaches”

6/27/03: McLean Hospital/Harvard Medical School Psychiatry in 2003 Conference, “Treatment of Patients with Substance Use Disorders and Psychiatric Illness”

10/29/03: Zucker Hillside Hospital, New York, “Substance Abuse and Mood Disorders”

1/9/04 Feldman Lectures, Grey Nuns Hospital, Edmonton, Alberta, Canada, “Treatment Strategies for Patients with Substance Abuse and Dual Diagnosis”

2/19/04 McLean Hospital/Harvard Medical School Pharmacology and Clinical Therapeutics Course, “Pharmacologic Management of Substance Abuse”

6/2/04: CAB Health and Recovery Services, Peabody, MA, “Substance Abuse and Mood Disorders”

9/8/04: Pembroke Hospital talk?

1/13/05: Tewksbury Hospital Substance Abuse Lecture Series, “Treatment of Patients with Substance Abuse and Bipolar Disorder”

2/1/05: Dartmouth-Hitchcock Medical Center Grand Rounds, “Substance Abuse and Bipolar Disorder”

2/15/05: Harvard Medical School Longwood Psychiatry Grand Rounds, “Treatment of Patients with Mood Disorders and Substance Abuse”

2/16/05: Springfield talk?

3/4/05: Cambridge Hospital/Harvard Medical School Addictions Conference, “Integrated Treatment for Mood and Substance Use Disorders: Understanding Personality Problems and Addictions”

3/8/05: Westwood Lodge Hospital, “The Treatment of Alcohol Dependence”

3/31/05: McLean Hospital Grand Rounds, “The Treatment of Patients with Substance Abuse and Bipolar Disorder”

5/13/05: Institut Philippe Pinel de Montreal, “Substance Abuse and Dual Diagnosis: New Treatment Approaches”

9/27/05: Tufts University School of Medicine, “Cocaine Addiction”

10/20/05: Brown University talk?

10/27/05: Tufts Health Care Institute Opioid Conference, “Opioid Abuse Resistance”

11/16/05: Northwest Association for Psychiatric Education and Advancement, New Brunswick, Canada,

“Substance Abuse and Dual Diagnosis: New Treatment Approaches”

12/19/05: Bournewood Hospital Grand Rounds, “Bipolar Disorder and Substance Abuse”

2/9/06: McLean Hospital Grand Rounds, “The Treatment of Alcohol Dependence”

6/15/06: McLean Hospital Psychiatry in 2006 Conference, “Treatment of Patients with Substance Use Disorders and Psychiatric Illness”

11/29/06: Melrose Wakefield Hospital Grand Rounds, “Substance Abuse: The Treatment of Alcohol Dependence”

1/4/07: University of Massachusetts School of Medicine Psychiatry Grand Rounds, “The Treatment of Patients with Bipolar and Substance Abuse”

2/16/07: North shore Medical Center Psychiatry Grand Rounds, “Treatment of Alcohol Dependence”

3/5/07: Tufts University School of Medicine Psychiatry Grand Rounds, “The Treatment of Patients with Bipolar and Substance Abuse”

3/30/07: University Psychiatric Institute, Quebec City, Canada, “The Treatment of Patients with Bipolar and Substance Use Disorders”

4/18/07: Centre for Addiction and Mental Health, Toronto, 14th Annual H. David Archibald Lecture for Outstanding Research and/or Practice in the Addictions, “The Treatment of Patients with Bipolar and Substance Use Disorders”

Continuing Medical Education Courses

1987- Faculty of McLean Hospital Board Review Course - Lecturer on substance use disorders, typically two hour-long presentations per year, 5 hours of preparation per year

Lecturer in the following Harvard Medical School Continuing Medical Education Course

Brigham & Women’s Hospital Intensive Review of Internal Medicine Course (twice)

Addiction Medicine Course (several times)

Cambridge Hospital Treating the Addictions Course (several times)

Massachusetts General Hospital Bipolar Disorder Mini-Fellowship (several times)

Massachusetts General Hospital Adolescent Substance Use Disorders Course

Cambridge Hospital Suicide Course

McLean Hospital Board Review, State-of-the-Art, Psychopharmacology Courses (many times)

Advisory and Supervisory Responsibilities in Clinical or Laboratory Setting

1979- Supervisor of medical students and psychiatric residents, McLean Hospital; supervised residents who rotate through the Substance Abuse Clinical Service; typically 50-70 hours per year depending on number of residents.

1999- Have overseen addiction psychiatry fellowship at McLean Hospital, and have supervised fellows in addiction psychiatry, one hour per week; Partners Addiction Psychiatry Fellowship became ACGME certified in 1999; director of fellowship at McLean Hospital, typically 80 hours per year.

Have acted as Mentor for several psychiatrists who were entering a clinical or research career in the addictions.

Leadership Roles

1987 Course organizer and lecturer, McLean Hospital/Harvard Medical School symposium on “Cocaine”

1998- Member, “Mind, Brain, and Behavior” Substance Abuse Working Group, Harvard University

1998- Member, Advisory Group on Division on Addictions, Harvard Medical School

1998 Course organizer and lecturer, McLean Hospital symposium on “New Developments in the Treatment of Substance Use Disorders”

2000- Board of Honors Tutors, Harvard University Department of Psychology (Faculty of Arts and Sciences)

Professional Leadership Roles Related to Teaching

1992 Organised first review course in addiction psychiatry for the American Academy of Addiction Psychiatry

1997- Chairman, Assessment Committee on Substance Abuse for Psychiatry, Core Clerkship and Psychiatry 700 MJ, Harvard Medical School

BIBLIOGRAPHY

Original Reports:

Weiss RD, Goldenheim PD, Mirin SM, Hales CA, Mendelson JH. Pulmonary dysfunction in cocaine smokers. Am J Psychiatry 1981;138:1110-1112.

Mirin SM, Weiss RD, Michael J. Alcohol abuse in patients dependent on other drugs. Psychiatr Annals 1982;12:430-433.

Weiss RD, Pope HG Jr, Mirin SM. Treatment of chronic cocaine abuse and attention deficit disorder,

Residual type, with magnesium pemoline. Drug Alcohol Depend 1985;15:69-72.

Weiss RD, Mirin SM. Substance abuse as an attempt at self-medication. Psych Med 1985;3:357-367.

Weiss RD, Mirin SM, Michael JL, Sollogub A. Psychopathology in chronic cocaine abusers. Am J Drug Alcohol Abuse 1986;12(1):17-29.

Weiss RD, Tilles DS, Goldenheim PD, Mirin SM. Decreased single breath carbon monoxide diffusing capacity in cocaine freebase smokers. Drug Alcohol Depend 1987;19:271-276.

Griffin ML, Weiss RD, Mirin SM, Wilson H, Bouchard-Voelk B. The use of the Diagnostic Interview Schedule in drug dependent patients. Am J Drug Alcohol Abuse 1987;13:281-291.

Mirin SM, Weiss RD, Michael J, Griffin ML. Psychopathology in substance abusers: Diagnosis and treatment. Am J Drug Alcohol Abuse 1988;14:139-157.

Mendelson JH, Teoh SK, Lange U, Mello NK, Weiss R, Skupny A, Ellingboe J. Anterior pituitary, adrenal and gonadal hormones during cocaine withdrawal. Am J Psychiatry 1988;145:1094-1098.

Weiss RD. Relapse to cocaine abuse after initiating desipramine treatment. JAMA 1988;260:2545-2546.

Weiss RD, Gawin FH. Protracted elimination of cocaine metabolites in long term high-dose cocaine abusers. Am J Medicine 1988;85:879-880.

Weiss RD, Mirin SM, Griffin ML, Michael JL. Psychopathology in cocaine abusers: Changing trends. J Nerv Ment Dis 1988;176:719-725.

Weiss RD, Mirin SM, Griffin ML, Michael JL. A comparison of alcoholic and non-alcoholic drug abusers. J Stud Alcohol 1988;49:510-515.

Griffin ML, Weiss RD, Mirin SM, Lange U. A comparison of male and female cocaine abusers. Arch Gen Psychiatry 1989;46:122-126.

Weiss RD, Mirin SM. The dual diagnosis alcoholic: Evaluation and treatment. Psychiatr Annals 1989;19:261-265.

Adelman SA, Weiss RD. What is therapeutic about inpatient alcoholism treatment? Hosp Community Psychiatry 1989;40:515-519.

Mirin SM, Weiss RD. Genetic factors in the development of alcoholism. Psychiatr Annals 1989;19:239-242.

Weiss RD, Griffin ML, Mirin SM. Diagnosing major depression in cocaine abusers: The use of depression rating scales. Psychiatry Res 1989;28:335-343.

Teoh SK, Mendelson JH, Mello NK, Weiss R, McElroy S, McAfee, B. Hyperprolactinemia and risk for relapse of cocaine abuse. Biol Psychiatry 1990;28:824-829.

Weiss RD, Mirin SM. Psychological and pharmacological treatment strategies in cocaine dependence. Ann Clin Psychiatry 1990;2:239-243.

Mirin SM, Weiss RD, Griffin ML, Michael JL. Psychopathology in drug abusers and their families. Compr Psychiatry 1991;32:36-51.

Kroft CL, Gescuk B, Woods BT, Mello NK, Weiss RD, Mendelson JH. Brain ventricular size in female alcoholics: An MRI study. Alcohol 1991;8:31-34.

Weiss RD, Mirin SM, Frances RJ. The myth of the typical dual diagnosis patient. Hosp Community Psychiatry 1992;43:107-108.

Greenfield SF, Weiss RD, Griffin ML. Patients who use drugs during inpatient substance abuse treatment. Am J Psychiatry 1992;149:235-239.

Weiss RD, Mirin SM, Griffin ML. Methodological considerations in the diagnosis of coexisting psychiatric disorders in substance abusers. Br J Addict 1992;87:179-187.

Hudson JI, Weiss RD, Pope HG Jr, McElroy SL, Mirin SM. Eating disorders in hospitalized substance abusers. Am J Drug Alcohol Abuse 1992;18:75-85.

Weiss RD, Collins DA. Substance abuse and psychiatric illness: The dually diagnosed patient. Am J Addict 1992;1(2):93-99.

Weiss RD, Griffin ML, Mirin SM. Drug abuse as self-medication for depression: An empirical study. Am J Drug Alcohol Abuse 1992;18:121-129.

Weiss RD, Griffin ML, Hufford C. Severity of cocaine dependence as a predictor of relapse to cocaine use. Am J Psychiatry 1992;149:1595-1596.

Weiss RD, Mirin SM, Griffin ML, Gunderson JG, Hufford C. Personality disorders in cocaine dependence. Compr Psychiatry 1993;34(3):145-149.

Najavits LM, Weiss RD. Variations in therapist effectiveness in the treatment of patients with substance use disorders: An empirical review. Addiction 1994;89:679-688.

Weiss RD, Hufford C, Mendelson JH. Serum prolactin levels and treatment outcome in cocaine dependence. Biol Psychiatry 1994;35:573-574.

Najavits LM, Weiss RD. The role of psychotherapy in the treatment of substance use disorders. Harvard Review of Psychiatry 1994;2:84-96.

Weiss RD, Griffin ML, Hufford C. Craving in hospitalized cocaine abusers as a predictor of outcome. Am J Drug Alcohol Abuse 1995;21(3):289-301.

Greenfield SF, Weiss RD, Tohen M. Substance abuse and the chronically mentally ill: A description of dual diagnosis treatment services in a psychiatric hospital. Community Ment Health J 1995;31:265-277.

Weiss RD, Najavits LM, Muenz LR, Hufford C. 12-Month test-retest reliability of the Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II) in cocaine dependent patients. Compr Psychiatry 1995;36:384-389.

Mirin SM, Batki SL, Bukstein O, Isbell PG, Kleber H, Schottenfeld RS, Weiss RD, Yandow VW. Practice guidelines for the treatment of patients with substance use disorders: Alcohol, Cocaine, Opioids. Am J Psychiatry 1995;152 Supple:11:5-59.

Najavits LM, Weiss RD, Liese BS. Group cognitive-behavioral therapy for women with PTSD and substance use disorder. J Subst Abuse Treat 1996;13(1):13-22.

Weiss RD, Martinez-Raga J, Hufford C. The significance of a coexisting opioid use disorder in cocaine dependence: an empirical study. Am J Drug Alcohol Abuse 1996;22(2):173-184.

Najavits LM, Griffin ML, Luborsky L, Frank A, Weiss RD, Liese BS, Thompson HT, Nakayama E, Siqueland L, Daley D, Onken LS. Therapists' emotional reactions to substance abusers: A new questionnaire and initial findings. Psychotherapy 1996;32:669-677.

Weiss RD, Griffin ML, Najavits LM, Hufford C, Kogan J, Thompson HJ, Albeck JH, Bishop S, Daley DC, Mercer D, Siqueland L. Self-Help activities in cocaine dependent patients entering treatment: Results from the NIDA Collaborative Cocaine Treatment Study. Drug Alcohol Depend 1996;43:79-86.

Barber JP, Frank A, Weiss RD, Blaine J, Siqueland L, Moras K, Calvo N, Chittams J, Mercer D, Salloum I. Prevalence and correlates of personality disorder diagnoses among cocaine dependent outpatients. J Pers Dis 1996;10:297-311.

Gorski NP, Nouraldin H, Dube DM, Preffer FI, Dombrowski DM, Villa EM, Lewandrowski KB, Weiss RD, Hufford C, Laposata M. Reduced fatty acid ethyl ester synthase activity in the white blood cells of alcoholics. Alcohol Clin Exp Res 1996;20(2):268-274.

Weiss RD, Martinez-Raga J, Griffin ML, Greenfield SF, Hufford C. Gender differences in cocaine dependent patients: a six-month follow-up study. Drug Alcohol Depend 1997;44:35-40.

Weiss RD, Griffin ML, Hufford C, Muenz LR, Najavits LM, Jansson SB, Kogan J, Thompson HJ. Early prediction of initiation of abstinence from cocaine: use of a craving questionnaire. Am J Addict 1997;6:224-231.

Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken L, Muenz L, Thase MF, Weiss RD, Gastfriend DR, Woody G, Barber JP, Butler SF, Daley D, Bishop S, Najavits LM, Lis J, Mercer D, Griffin ML, Moras K, Beck AT. The NIDA collaborative cocaine treatment study: rationale and methods. Arch Gen Psychiatry 1997;54:721-726.

Najavits LM, Weiss RD, Shaw SR. The link between substance abuse and posttraumatic stress disorder in women: a research review. Am J Addict 1997;6:273-283.

Weiss RD, Najavits LM, Greenfield SF, Soto JA, Shaw SR, Wyner D. Validity of substance use self-reports in dually diagnosed outpatients. Am J Psychiatry 1998:155:127-128.

Najavits LM, Weiss RD, Reif S, Gastfriend DR, Siqueland L, Barber JP, Butler SF, Thase M, Simon Onken L. The Addiction Severity Index as a screen for trauma and posttraumatic stress disorder. J Stud Alcohol 1998;59:56-62.

Maas LC, Lukas SE, Kaufman MJ, Weiss RD, Daniels SL, Rogers VW, Kukes TJ, Renshaw PF. Functional Magnetic Resonance Imaging of human brain activation during cue-induced cocaine craving. Am J Psychiatry 1998;155:124-126.

Najavits LM, Gastfriend DR, Barber JP, Reif S, Muenz LR, Blaine J, Frank A, Crits-Christoph P, Thase M, Weiss RD. Cocaine dependence with and without PTSD Among Subjects in the National Institute on Drug Abuse collaborative cocaine treatment study. Am J Psychiatry 1998;155:214-219.

Greenfield SF, Weiss RD, Muenz LR, Vagge LM, Kelly JF, Bello LR, Michael J. The effect of depression on return to drinking: a prospective study. Arch Gen Psychiatry 1998;55:259-265.

Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, Griffin ML. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998;59:172-174.

Najavits LM, Weiss RD, Shaw SR, Muenz LR. “Seeking safety”: Outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence. J Traumatic Stress 1998;11:437-456 .

Tohen M, Greenfield SF, Weiss RD, Zarate CA, Vagge LM. The effect of comorbid substance use disorders on the course of bipolar disorder: A review. Harvard Rev Psychiatry 1998;6:133-141.

Siqueland L, Crits-Christoph P, Frank A, Daley D, Weiss RD, Chittams J, Blaine U, Luborsky L. Predictors of dropout from psychosocial treatment of cocaine dependence. Drug Alcohol Depend 1998;52:1-13.

Weiss RD, Najavits LM, Greenfield SF. A relapse prevention group for patients with bipolar and substance use disorders. J Subst Abuse Treat 1999;16(1):47-54.

Barber JP, Luborsky L, Crits-Christoph P, Thase ME, Weiss R, Frank A, Onken L, Gallop R. Therapeutic alliance as a predictor of outcome in treatment of cocaine dependence. Psychotherapy Research 1999;9:54-73.

Siqueland L, Horn A, Moras K, Woody G, Weiss R, Blaine J, Bishop S, Barber J, Thase M. Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine dependent sample. Am J Addict 1999;8:165-169.

Wines JD, Weiss RD. Opioid withdrawal during risperidone treatment. J Clin Psychopharmacol 1999;19:265-267.

Najavits LM, Weiss RD, Shaw SR: A clinical profile of women with posttraumatic stress disorder and substance dependence. Psychology of Addictive Behaviors 1999;13:98-104.

Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken L, Muenz L, Thase ME, Weiss RD, Gastfriend DR, Woody G, Barber JP, Butler SF, Daley D, Salloum I, Bishop S, Najavits LM, Lis J, Mercer D, Griffin ML, Moras K, Beck AT. Psychosocial treatments for cocaine dependence: results of the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999;56:493-502.

Rounsaville BJ, Weiss RD, Carroll KM. Options for managing psychotropic medications in drug-abusing patients participating in behavioral therapies clinical trials. Am J Addict 1999;8:178-189.

Greenfield SF, Hufford MR, Vagge LM, Muenz L, Costello M, Weiss R. The relationship of self-efficacy expectancies to relapse among alcohol dependent men and women: a prospective study. J Stud Alcohol 2000;61:345-351.

Weiss RD, Griffin ML, Greenfield SF, Najavits LM, Wyner D, Soto JA, Hennen JA. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. J Clin Psychiatry 2000;61:361-367.

Weiss RD, Griffin ML, Gallop R, Onken LS, Gastfriend DR, Daley D, Crits-Christoph P, Bishop S, Barber JP. Self-help group attendance and participation among cocaine dependent patients. Drug Alcohol Depend 2000;60:169-177.

Weiss RD, Greenfield SF, Griffin ML, Najavits LM, Fucito LM. The use of collateral reports for patients with bipolar and substance use disorders. Am J Drug Alcohol Abuse 2000;26(3):369-378.

Najavits LM, Weiss RD, Nelson SR, Dierberger A. Psychotherapists’ views of treatment manuals. Professional Psychology: Research and Practice 2000;31(4):404-408.

Weiss RD, Griffin ML, Gallop R, Luborsky L, Siqueland L, Frank A, Onken LS, Daley DC, Gastfriend DR. Predictors of self-help group attendance in cocaine dependent patients. J Stud Alcohol 2000;61:714-719.

Weiss RD, Kolodziej ME, Najavits LM, Greenfield SF, Fucito LM. Utilization of psychosocial treatments by patients diagnosed with bipolar disorder and substance dependence. Am J Addict 2000;9:314-320.

Dickey B, Azeni H, Weiss R, Sederer L. Schizophrenia, substance use disorder and medical co-morbidity. J Mental Health Policy Econ 2000;3:1:1327-1333.

Barber JP, Luborsky L, Gallop R, Crits-Christoph P, Frank A, Weiss RD, Thase ME, Connolly MB, Gladis M, Foltz C, Siqueland L. Therapeutic alliance as a predictor of outcome and retention in the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. J Consult Clin Psychol 2001;69:119-124.

Crits-Christoph P, Siqueland L, McCalmont E, Weiss RD, Gastfriend DR, Frank A, Moras K, Barber JP, Blaine J, Thase ME. Impact of psychosocial treatments on associated problems of cocaine dependent patients. J Consult Clin Psychol 2001;69(5):825-830.

Greenfield SF, Kolodziej ME, Sugarman DE, Muenz LR, Vagge LM, He DY, Weiss RD. History of abuse and drinking outcomes following inpatient alcohol treatment: a prospective study. Drug Alcohol Depend 2002;67:227-234.

Dickey B, Normand ST, Weiss RD, Drake RE, Azeni H. Medical morbidity, mental illness and substance use disorders. Psychiatric Services 2002;53:861-867.

Kanayama G, Cohane GH, Weiss RD, Pope HG Jr. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? J Clin Psychiatry 2003;64:156-160.

Greenfield SF, Hennessy G, Sugarman D, Weiss R. What general psychiatrists ask addiction psychiatrists: A review of 381 substance abuse consultations in a psychiatric hospital. Am J Addict 2003;12:18-28.

Weiss RD, Griffin ML, Mazurick C, Berkman B, Gastfriend DR, Frank A, Barber JP, Blaine J, Salloum I, Moras K. The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use. Am J Psychiatry 2003;160:1320-1325.

Greenfield SF, Sugarman DE, Muenz LR, Patterson MD, He DY, Weiss RD. The relationship between educational attainment and relapse among alcohol-dependent men and women: a prospective study. Alcohol Clin Exp Res 2003;27:1278-1285.

Crits-Christoph P, Gibbons MBC, Barber JP, Gallop R, Beck AT, Mercer D, Tu X, Thase ME, Weiss RD, Frank Mediators of Outcome of Psychosocial Treatments for Cocaine Dependence. J Consult Clin Psychol 2003;71(5):918-925.

The COMBINE Study Research Group. 1 Testing combined pharmacotherapies and behavioral interventions in alcohol dependence (The COMBINE Study): A pilot feasibility study. Alcohol Clin Exp Res 2003;27(7):1123-1131.

The COMBINE Study Research Group. 1 Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: Rationale and methods. Alcohol Clin Exp Res 2003;27(7):1107-1122.

Dickey B, Normand ST, Drake R, Weiss RD, Azeni H, Hanson A. Limiting inpatient substance use treatment: What are the consequences? Medical Care Research and Review 2003;60(3):332-346.

Weiss RD, Kolodziej M, Griffin ML, Najavits LM, Jacobson LM, Greenfield SF. Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence. J Affect Disord 2004;79:279-283.

Najavits LM, Sullivan TP, Schmitz M, Weiss RD, Lee CSN. Treatment utilization of women with PTSD and substance dependence. Am J Addict 2004;13:215-224.

Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 2004;99:1382-1392.

Najavits LM, Sonn J, Walsh M, Weiss RD. Domestic violence in women with PTSD and substance abuse. Addict Behav 2004;29:707-715.

Najavits LM, Gotthardt S, Weiss RD, Epstein M. Cognitive distortions in the dual diagnosis of PTSD and substance use disorders. Cognitive Therapy and Research 2004;28:159-172.

Najavits LM, Ghinassi F, Van Horn A, Weiss RD, Siqueland L, Frank A, Thase ME, Luborsky L, Onken LS. Therapist satisfaction with four manual-based treatments on a national multisite trial: an exploratory study. Psychotherapy, Theory, Research, Practice, Training 2004;41:26-34.

Potter JS, Hennessy G, Borrow JA, Greenfield SF, Weiss RD. Substance use histories in patients seeking treatment for CR oxycodone dependence. Drug Alcohol Depend 2004;76:213-215.

Humphreys K, Wing S, McCarty D, Chappel J, Gallant L, Haberle B, Horvath AT, Kaskutas LA, Kirk T, Kivlahan D, Laudet A, McCrady BS, McLellan AT, Morgenstern J, Townsend M, Weiss R. Self-help organizations for alcohol and drug problems: Toward evidence-based practice and policy. J Subst Abuse Treat 2004;26:151-158.

Weiss RD. Treating patients with bipolar disorder and substance dependence: lessons learned. J Subst Abuse Treat 2004;27:307-312.

Weiss RD, Jaffee WB, de Menil VP, Cogley CB. Group therapy for substance use disorders: What do we know? Harvard Rev Psychiatry 2004;12:339-350.

Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E, Nierenberg AA, Calabrese JR, Sachs GS, Pollack MH; STEP-BD Investigators. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol 2004;24(5):512-520.

Weiss RD, Ostacher M, Otto MW, Calabrese JR, Fossey M, Wisniewski SR, Bowden C, Nierenberg AA, Pollack MH, Salloum I, Simon NM, Thase ME, Sachs GS. Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry 2005;66:730-735.

Gelernter J, Panhuysen C, Weiss R, Brady K, Hesselbrock V, Rounsaville B, Poling J, Wilcox M, Farrer L,Kranzler, HR. Genomewide linkage scan for cocaine dependence and related traits: significant linkages for a cocaine-related trait and cocaine-induced paranoia. Am J Med Genet B Neuropsychiatr Genet 2005:136:45-52.

Weiss RD, LoCastro JS, Swift R, Zweben A, Miller WR, Longabaugh R, Hosking JD. The use of a “psychotherapy with no pills” treatment condition as part of a combined pharmacotherapy-psychotherapy research study of alcohol dependence. J Stud Alcohol 2005;15(Suppl):43-49.

Pettinati HM, Weiss RD, Dundon W, Miller WR, Donovan D, Ernst DB, Rounsaville BJ. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol 2005;15(Suppl):170-178.

Greenfield SF, Sugarman DE, Nargiso J, Weiss RD. Readability of patient handout materials in a nationwide sample of alcohol and drug abuse treatment programs. Am J Addict 2005;14:339-345.

Kolodziej ME, Griffin ML, Najavits LM, Otto MW, Greenfield SF, Weiss RD. Anxiety disorders among patients with co-occurring bipolar and substance use disorders. Drug Alcohol Depend 2005;80:251-257.

Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11:315-337.

Weiss RD, Griffin ML, Gallop RJ, Najavits LM, Frank A, Crits-Christoph P, Thase ME, Blaine J, Gastfriend DR, Daley D, Luborsky L. The effect of twelve-step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients. Drug Alcohol Depend 2005;77:177-184.

Najavits LM, Schmitz M, Gotthardt S, Weiss RD. Seeking safety plus exposure therapy: an outcome study on dual diagnosis men. J Psychoactive Drugs 2005;27:425-435.

Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-2017.

Kalayasiri R, Kranzler HR, Weiss R, Brady K, Gueorguieva R, Panhuysen C, Yang B-Z, Farrer L, Gelernter J, Malison RT. Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug Alcohol Depend 2006;84:77-84.

Yu Yi CP, Kranzler HR, Hesselbrock V, Rounsaville B, Weiss R, Brady K, Farrer LA, Gelernter J. Intronic variants in the DOPA Decarboxylase (DDC) Gene are associated with smoking behavior in European- Americans and African-Americans. Hum Mol Genet 2006;15:2192-2199.

Gelernter J, Panhuysen C, Wilcox M, Hesselbrock V, Rounsaville B, Poling J, Weiss R, Sonne S, Zhao H, Farrer L, Kranzler HR. Genomewide linkage scan for opioid dependence and related traits. Am J Hum Genet 2006;78:759-769.

Harned MS, Najavits LM, Weiss RD. Self-harm and suicidal behavior in women with comorbid PTSD and substance dependence. Am J Addict 2006;15(5):392-395.

Ostacher MJ, Nierenberg AA, Perlis RH, Eidelman P, Borrelli DJ, Tran TB, Ericson GM, Weiss RD, Sachs GS. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry 2006;67:1907-1911.

Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, Frank E, Nierenberg AA, Marangell LB, Sagduyu K, Weiss RD, Miyahara S, Thase ME, Sachs GS, Pollack MH. Prospective 12-month course of bipolar disorder in outpatients with and without comorbid anxiety disorder. Br J Psychiatry 2006;189:20-25.

Fossey MD, Otto MW, Yates WR, Wisniewski SR, Gyulai L, Allen MH, Miklowitz DJ, Coon KA, Ostacher M, Neel J, Thase ME, Sachs GS, Weiss RD. Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: Data from the First 1000 STEP-BD participants. Am J Addict 2006;15(2):138-143.

Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol 2006;26(6Suppl1):S37-S42.

Miller WR, Baca C, Compton WM, Ernst D, Manuel JK, Pringle B, Schermer CR, Weiss RD, Willenbring ML, Zweben A. Addressing substance abuse in health care settings. Alcohol Clin Exp Res 2006;30(2):292-302.

Najavits LM, Gallop RJ, Weiss RD. Seeking Safety therapy for adolescent girls with PTSD and substance use disorder: A randomized controlled trial. J Behav Health Serv Res 2006;33(4):453-463.

Gelernter J, Yu Y, Weiss R, Brady K, Panhuysen C, Yang BZ, Kranzler HR, Farrer L. Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum Mol Genet 2006;15:3498-3507.

Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, Doreau, HR, Hennen JA. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 2007;164:100-107.

Meade CS, Weiss, RD. Substance abuse as a risk factor for HIV sexual risk behavior among persons with severe mental illness: Review of evidence and exploration of mechanisms. Clin Psychol Sci Prac 2007; 14:23-33.

Manwani SG, Szilagi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J Clin Psychiatry 2007; 68:1172-1176.

Pomykacz B, Mao M, Weiss RD, Teter CJ. A review of brief medication-adherence instruments used in patients with schizophrenia and bipolar disorder. Harvard Rev Psychiatry 2007;15:259-263.

Shields AL, Howell RT, Potter JS, Weiss RD. The Michigan Alcoholism Screening Test and its shortened forms: a meta-analytic inquiry into score reliability. Subst Use Misuse 2007;42:1783-1800.

Jaffee WB, Trucco E, Levy S, Weiss RD. Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing. J Subst Abuse Treat 2007;33:33-42.

Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfield SF, Kosten TR, O’Brien CP, Rounsaville BJ, Strain EC, Ziedonis DM, Hennessy G, Connery HS, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT,Johnson BR, Nininger JE, Summergrad P, Woods SM, Yager J, Pyles R, Cross CD, Peele R, Shemo JP, Lurie L, Walker RD, Barnovitz MA,Gray SH, Saxena S, Tonnu T, Kunkle R, Albert AB, Fochtmann LJ, Hart C, Regier D. Work group on substance use disorders; American Psychiatric Association; Steering Committee on Practice Guidelines. Treatment of Patients with Substance Use Disorders, Second edition. American Psychiatric Association. Am J Psychiatry 2007;164(4 Suppl):5-123.

Gelernter J, Panhuysen C, Weiss R, Brady K, Poling J, Krauthammer M, Farrer L, Kranzler HR. Genomewide linkage scan for nicotine dependence: Identification of a novel chromosome 5 risk locus. Biol Psychiatry 2007;61:119-126.

Meade CS, Graff FS, Griffin ML, Weiss RD. HIV risk behavior among patients with co-occurring bipolar and substance use disorders: Associations with mania and drug abuse. Drug Alcohol Depend 2008;92:296-300.

Kranzler HR, Wilcox M, Weiss RD, Brady K, Hesselbrock V, Rounsaville B, Farrer L, Gelernter J. The validity of cocaine dependence subtypes. Addict Behav 2008;33:41-53.

Kolodziej ME, Griffin ML, Bender R, Weiss RD. Assessment of depressive symptom severity among patients with co-occurring bipolar disorder and substance dependence. J Affect Disord 2008;106:83-89.

The COMBINE Study Research Group. 2 Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): Examination of posttreatment drinking outcomes. J Stud Alcohol Drugs 2008;69:5-13.

Jaffee WB, Trucco E, Teter C, Levy S, Weiss RD. Ensuring validity in uring drug testing. Psychiatr Serv 2008;59:140-142.

Barber JP, Gallop R, Crits-Christoph P, Frank A, Thase ME, Weiss RD, Connolly Gibbons MB. The role of therapist adherence, therapist competence, and the alliance in predicting outcome of individual drug counseling: Results from the NIDA Collaborative Cocaine Treatment Study. Psychotherapy Research, in press.

Crits-Christoph P, Gibbons MBC, Barber JP, Gallop R, Weiss RD. Predictors of sustained abstinence during psychosocial treatments for cocaine dependence. J Psychother Pract Res, in press.

Miller CS, Shields AL, Campfield D, Wallace KA, Weiss RD. Substance use scales of the Minnesota Multiphasic Personality Inventory: An exploration of score reliability via meta-analysis. Educational and Psychological Measurement, in press.

Shields AL, Campfield D, Miller CS, Howell RT, Wallace KA, Weiss RD. Score reliability of adolescent alcohol use screening measures: A meta-analytic inquiry. J Child Adolesc Subst Use, in press.

Bender RE, Griffin ML, Gallop RJ, Weiss RD. Assessing negative consequences in patients with substance use and bipolar disorders: Psychometric properties of the Short Inventory of Problems (SIP). Am J Addict, in press.

Potter JS, Prather K, Weiss RD. Physical pain and associated clinical characteristics in treatment-seeking patients in four substance use disorder treatment modalities. Am J Addict, in press.

Potter JS, Shiffman SJ, Weiss RD. Chronic pain severity in opioid-dependent patients. Am J Drug Alcohol Abuse, in press.

Bieber CM, Fernandez K, Borsook D, Brennan MJ, Butler SF, Jamison R, Osgood E, Potter JS, Thomson HN, Weiss RD, Katz NP. Retrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: a pilot case-control study. Exp Clin Psychopharmacol, in press.

Worley M, Gallop R, Gibbons MBC, Ring-Kurtz S, Present J, Weiss RD, Crits-Christoph P. Additional treatment services in a cocaine treatment study: level of services obtained and impact on outcome. Am J Addict, in press.

Graff FS, Griffin ML, Weiss RD. Predictors of dropout from group therapy among patients with bipolar and substance use disorders. Drug Alcohol Depend, in press.

Levy B, Monzani BA, Stephansky MR, Weiss RD. Neurocognitive impairment in patients with co-occurring bipolar disorder and alcohol dependence upon discharge from inpatient care. Psychiatr Res, in press.

Ernst DB, Pettinati HM, Weiss RD, Donovan DM, Longabaugh R. Relating elements of medical management to patient outcomes in treating alcohol dependence. Ann Fam Med, in press.

Yu Y, Kranzler HR, Panhuysen C, Weiss RD, Poling J, Farrer LA, Gelernter J. Substance dependence low density whole genome association study in two distinct American populations. Hum Genet, in press.